NEW ANTIBACTERIAL AGENTS FOR TREATMENT OF GRAM-POSITIVE INFECTIONS

摘要

1. The compound of formula (I) and its pharmaceutically acceptable salts, where: R is and v is an integer from 3 to 7.2. A compound of formula (II) and a pharmaceutically acceptable salt thereof. 3. A pharmaceutical composition comprising a compound according to claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. A method for treating or preventing a bacterial infection, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition according to Claim 3.5. The method of claim 4, wherein the object is a human, animal, cell culture or plant. The method of claim 5, wherein the object is a human. The method of claim 4, wherein the bacterial infection is caused by gram-positive bacteria. The method of claim 7, wherein the bacterium is a strain. The method of claim 8, wherein the strain is a Nap1.10 strain. The method of claim 7, wherein the bacterium is a bacterium resistant to antibiotics. The method of claim 10, wherein the antibiotic-resistant bacterium is daptomycin-resistant Staphylococcus aureus, daptomycin-resistant, daptomycin-resistant, methicillin-resistant, or a mixture of bacteria comprising at least one of the antibiotic-resistant bacteria. The method of claim 10, wherein the antibiotic-resistant bacterium is resistant to vancomycin, methicillin, glycopeptide antibiotics, penicillin or daptomycin. The method of claim 7, wherein the bacterial infection is a disease associated with (CDAD). The method of claim 13, wherein the disease associated with occurs as a result of an infection and is exacerbated by a Nap1.15 infection. The use of the compound according to claim 2 for the preparation of a medicinal product for